BioCentury
ARTICLE | Clinical News

EB-1010: Phase IIb/IIIa started

March 21, 2011 7:00 AM UTC

Euthymics began the placebo-controlled, double-blind, U.S. Phase IIb/IIIa TRIADE trial to compare 50 and 100 mg EB-1010 vs. Paxil paroxetine for 12 weeks in about 300 patients. Euthymics gained the c...